Production of prostaglandin E2 in response to infection with modified vaccinia Ankara virus  by Pollara, Justin J. et al.
Virology 428 (2012) 146–155Contents lists available at SciVerse ScienceDirectVirology0042-68
http://d
n Corr
E-m
spesock
scott_la
1 Cu
Durham
2 Cujournal homepage: www.elsevier.com/locate/yviroProduction of prostaglandin E2 in response to infection with modiﬁed
vaccinia Ankara virusJustin J. Pollara a,1, April H. Spesock b,2, David J. Pickup b,c, Scott M. Laster a, Ian T.D. Petty a,n
a Department of Microbiology, North Carolina State University, Raleigh, NC 27695, USA
b Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
c Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USAa r t i c l e i n f o
Article history:
Received 3 March 2012
Accepted 26 March 2012
Available online 23 April 2012
Keywords:
Poxvirus
Vaccine
Lipid mediator
Cyclooxygenase-2
Cytosolic phospholipase A2
NF-kB22/$ - see front matter & 2012 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2012.03.019
esponding author. Fax: þ1 919 515 7867.
ail addresses: justin.pollara@duke.edu (J.J. Pol
a@medimmune.com (A.H. Spesock), picku001
ster@ncsu.edu (S.M. Laster), tim_petty@ncsu.
rrent address: Department of Surgery, Duk
, NC 27710, USA.
rrent address: MedImmune, Santa Clara, CAa b s t r a c t
Prostaglandin E2 (PGE2) is an arachidonic acid (AA)-derived signaling molecule that can inﬂuence host
immune responses to infection or vaccination. In this study, we investigated PGE2 production in vitro by
cells infected with the poxvirus vaccine strain, modiﬁed vaccinia Ankara virus (MVA). Human THP-1
cells, murine bone marrow-derived dendritic cells, and murine C3HA ﬁbroblasts all accumulated PGE2
to high levels in culture supernatants upon infection with MVA. We also demonstrated that MVA
induced the release of AA from infected cells, and this was, most unusually, independent of host
cytosolic phospholipase A2 activity. The accumulation of AA and PGE2 was dependent on viral gene
expression, but independent of canonical NF-kB signaling via p65/RelA. The production of PGE2
required host cyclooxygenase-2 (COX-2) activity, and COX-2 protein accumulated during MVA
infection. The results of this study provide insight into a novel aspect of MVA biology that may affect
the efﬁcacy of MVA-based vaccines.
& 2012 Elsevier Inc. All rights reserved.Introduction
Prostaglandins (PGs) are a group of fatty acid-derived signaling
molecules that regulate a myriad of physiological and pathological
processes. Viruses of many types have been shown to induce the
production of PG upon infection (Reynolds and Enquist, 2006; Steer
and Corbett, 2003). In some cases, PGs may affect the outcome of a
virus infection, either by mediating direct, cell-autonomous effects
on viral replication, or throughmodulation of innate and/or adaptive
immune responses. Unsurprisingly, examples of viral inhibition of
PG production in response to exogenous stimuli have also been
described (Culver and Laster, 2007; Savard et al., 2000), which
suggests that some viruses have the capacity to manipulate this
important host response to their own advantage.
One of the most ubiquitous and best-characterized PG sub-
types is prostaglandin E2 (PGE2). The biological responses asso-
ciated with PGE2 signaling have long been known to include
key roles in the mediation of inﬂammation (Dubois et al., 1998;
Ivanov and Romanovsky, 2004; Portanova et al., 1996). Morell rights reserved.
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e University Medical Center,
95054, USA.recently, PGs have also been found to have important roles in
shaping both cell-mediated and humoral immune responses. In
most cases, PGE2 has been shown to polarize the immune system
towards generation of a T helper type 2 (Th2)-biased response.
Examples of PGE2-mediated effects include the reduction of Th1
cytokine production by T cells, macrophages, and NK cells, and the
promotion of IgG1 and IgE class-switching by B cells (reviewed by
Harizi and Gualde, 2005; Harris et al., 2002; Phipps et al., 1991).
Additionally, both human and murine dendritic cells (DCs) have
been shown to produce PGE2, as well as respond to PGE2 signaling
(Fogel-Petrovic et al., 2004; Harizi et al., 2001, 2002). PGE2 promotes
migration and survival of DCs, and suppresses their ability to
produce IL-12p70 (reviewed by Harizi and Gualde, 2005; Harris
et al., 2002). Thus, PGE2 can play a critical role during innate and
adaptive immune responses, and has functions complementary to
those of more widely studied, protein-based signaling molecules.
Modiﬁed vaccinia Ankara virus (MVA), a promising live-virus
vaccine platform, is a highly attenuated form of vaccinia virus
(VAC) strain Ankara that is avirulent in humans (Moss et al., 1996;
Stickl et al., 1974), yet remains effective as a vaccine against
virulent poxviruses (Earl et al., 2004; Mayr et al., 1978; Wyatt
et al., 2004). Due to its safety and immunogenicity, MVA is also
a candidate vaccine vector for cancer immunotherapy, and
for prophylaxis against various infectious diseases (reviewed by
Gomez et al., 2008; Rimmelzwaan and Sutter, 2009; Sutter and
Staib, 2003). During its attenuation by repeated passage in cell
culture, MVA lost many accessory genes found in related poxviruses,
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J.J. Pollara et al. / Virology 428 (2012) 146–155 147and therefore it often differs greatly from them in its capacity to
disrupt host responses (Antoine et al., 1998; Blanchard et al., 1998).
Because of the potential for widespread use of MVA in human
populations as a vaccine, or vaccine vector, there is a need to
increase our understanding of the characteristics of MVA during its
host–virus interactions.
Although substantial research has been conducted on the
diverse immune modulation strategies of poxviruses, the PG
response following poxvirus infection has received compara-
tively little attention. Recent in vivo studies with VAC have
shown directly that PGE2 is an important determinant of the
extent and type of immune responses initiated upon virus
infection, or as a consequence of vaccination with live-virus
vaccines and vaccine vectors (Bernard et al., 2010; Chang et al.,
2009). In vitro, the synthesis of PGs from exogenously
added eicosanoid precursors was found to be enhanced during
infection of monkey kidney cells with several poxviruses,
including MVA (Palumbo et al., 1993, 1994). However, these
studies did not address whether poxvirus infection alone was
sufﬁcient to induce PG production, nor were the biochemical
pathways used for PG biosynthesis investigated in poxvirus-
infected cells.
In the absence of exogenously added precursor molecules, de
novo synthesis of PGs normally is initiated by the enzymatic release
of arachidonic acid (AA) from membrane glycerophospholipids
(reviewed by Smith, 1989). Several cellular phospholipases may
be involved in this process; however, cytosolic phospholipase A2
(cPLA2) is often regarded as the most important enzyme because
cells obtained from cPLA2 knock-out mice are severely deﬁcient in
PG production in response to a variety of stimuli (Gijon et al., 2000;
Sapirstein and Bonventre, 2000). Phospholipase-released AA is then
converted into the intermediate prostaglandin H2 (PGH2) by cellular
cyclooxygenase (COX) enzymes. There are two predominant iso-
zymes of COX; COX-1 is most often constitutively expressed, and
has roles in tissue homeostasis, while COX-2 typically has low basal
expression, but is readily inducible (Smith et al., 1996; Tsatsanis
et al., 2006). The ﬁnal step of PG biosynthesis is the enzymatic
conversion of COX-generated PGH2 to PGE2, or other PG subtypes, by
speciﬁc PG synthases (Park et al., 2006).
In the current study we describe MVA-induced production of
PGE2 by human THP-1 cells, as well as by murine bone marrow
derived DCs and a murine ﬁbroblast cell line. We found that MVA
induced the accumulation of COX-2 protein in infected cells and
caused AA to be released from cellular membranes by a mechanism
that was independent of host cPLA2 activity. The production of
PGE2 by MVA-infected cells was dependent on COX-2 activity but
independent of canonical NF-kB signaling via p65/RelA. The produc-
tion of PGE2 in response to infection with MVA may contribute to
the immune response generated by MVA-based vaccines.0 12 24
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Fig. 1. MVA infection does not induce PGE2 production or release of AA by BS-C-1
cells. (A) BS-C-1 cells were mock infected, infected with MVA, or infected with VAC,
each at 5 PFU/cell. Culture supernatants were collected 24 h after infection and
concentrations of PGE2 were measured by ELISA. Data are means and SEM from
three independent experiments. (B) BS-C-1 cells were radiolabeled with [3H]AA
overnight and then mock infected, treated with PMA and A23187 (10 ng/ml PMA,
10 mM A23187), or infected with MVA or VAC, each at 5 PFU/cell. Culture
supernatants were collected 0, 2, 6, 12, and 24 h after infection and 200 mL aliquots
were subjected to liquid scintillation counting to determine release of [3H]AA
(CPM). Data plotted are means and SEM, from three independent experiments.Results
MVA infection alone does not lead to the accumulation of PGE2, or
arachidonic acid, in culture supernatants of BS-C-1 cells
Previous reports have described the accumulation of PGE2 in
poxvirus-infected BS-C-1 cell cultures following treatment with the
calcium ionophore A23187 and addition of radiolabeled linoleic
acid, an eicosanoid precursor (Palumbo et al., 1993, 1994). However,
it is not clear from the results of these studies whether poxvirus
infection alone was sufﬁcient to induce PG synthesis, nor was it
determined whether PGE2 was contained within the cells or released
into the culture supernatant where it could effect signaling. Conse-
quently, we evaluated the ability of MVA to induce the accumulation
of PGE2 in the culture supernatants of BS-C-1 cells under normalinfection conditions in vitro, in the absence of additional exogenous
treatments. BS-C-1 cells were infected with MVA at 5 PFU/cell, and
the concentration of PGE2 in culture supernatants was measured by
ELISA 24 h after infection. As shown in Fig. 1A, MVA infection alone
was not sufﬁcient to cause the accumulation of PGE2 in culture
supernatants. Because MVA is highly divergent from other pox-
viruses and replication-deﬁcient in most mammalian cells, as a
control, we also investigated the ability of replication-competent
VAC (strain Western Reserve) to induce PGE2 production by BS-C-1
cells. As seen for MVA, VAC infection did not result in the
accumulation of PGE2 in BS-C-1 cell culture supernatants. These
data indicate that neither MVA, nor VAC, can induce PGE2 produc-
tion by BS-C-1 cells under normal infection conditions.
In the absence of exogenously added eicosanoid precursor
molecules, the biosynthesis of PGE2 is dependent on the enzy-
matic release of AA from membrane glycerophospholipids. Thus,
we reasoned that the failure of BS-C-1 cells to produce PGE2
under our experimental conditions might result from an inabil-
ity of poxvirus infection to stimulate AA release from cellular
membranes. To evaluate this possibility, the liberation of AA
from virus-infected cells was measured by liquid scintillation
counting of [3H]AA accumulation in the culture supernatant of
radiolabeled BS-C-1 cells at various times after infection. The
release of AA could be stimulated by treatment of BS-C-1 cells
with phorbol 12-myristate 13-acetate (PMA) and A23187
together, as shown in Fig. 1B. In contrast, there was no detect-
able release of AA above that seen from mock-infected control
cells when cells were infected with VAC, and AA release was only
weakly stimulated between 12 and 24 h after infection with
MVA (Fig. 1B). These results suggest that the inability of BS-C-1
cells to produce measurable concentrations of PGE2 upon infec-
tion with MVA or VAC is likely due to the lack of virus-induced
AA release.
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murine DCs and a murine ﬁbroblast cell line
To evaluate whether the inability of MVA to induce PGE2 produc-
tion in BS-C-1 cells represented a cell type-dependent effect, we
investigated additional cell culture systems. Upon differentiation,
human THP-1 cells become macrophage-like, and in previous studies
they have been shown to produce chemokines, and certain cytokines,
in response to infection with MVA (Delaloye et al., 2009; Lehmann
et al., 2009). THP-1 cells were differentiated by treatment with PMA,
and then either mock-infected, or infected with MVA at 5 PFU/cell.
Culture supernatants were collected 24 h after infection, and PGE2
concentrations were determined by ELISA. As shown in Fig. 2A, MVA
infection of THP-1 cells caused robust accumulation of PGE2 in
culture supernatants.
Because MVA is intended to be used as a vaccine, we were also
interested in its effect on PG production by cells that are directly
involved in the generation of vaccine-induced immune responses.Mock MVA
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Fig. 2. Human and murine cells produce PGE2 in response to MVA infection. Human
THP-1 cells that had been differentiated with PMA (A), murine DCs (B), or C3HA
murine ﬁbroblasts (C) were mock-infected, or infected with MVA at 5 PFU/cell. Culture
supernatants were collected 24 h after infection and PGE2 concentrations were
measured by ELISA. Data are means and SEM from three (A,C) or ﬁve (B) experiments.DCs have critical roles in initiating and inﬂuencing adaptive
immune responses, and it has recently been shown that MVA
preferentially targets DCs over other subsets of hematolymphoid
cells both in vitro and in vivo (Liu et al., 2008). We therefore
investigated whether infection of murine DCs with MVA could
induce a PGE2 response. Murine DCs were generated in vitro from
bone marrow cells, and were either mock-infected, or infected
with MVA at 5 PFU/cell. Consistent with previous reports (Liu
et al., 2008), we found that MVA was taken up by murine DCs and
expressed viral genes, but the cells were non-permissive for viral
replication (data not shown). The PGE2 produced by murine DCs
was measured in culture supernatants 24 h after infection. As
shown in Fig. 2B, we found abundant accumulation of PGE2 in the
culture supernatants of MVA-infected murine DCs.
Further characterization of MVA-induced PGE2 production
would be facilitated by the ability to work in an established,
adherent cell line that does not require differentiation, so we also
evaluated the potential use of C3HA cells as a model system. This
mouse ﬁbroblast line was used previously to study the biochem-
ical pathways responsible for PG production during adenovirus
infection (Culver and Laster, 2007). In common with many other
cell lines (Blanchard et al., 1998; Caroll and Moss, 1997), we
found that C3HA cells were not infected productively by MVA, but
both early and late viral genes were expressed (data not shown).
As for the other cell types investigated, C3HA cells were mock-
infected, or infected with MVA at 5 PFU/cell, and the accumula-
tion of PGE2 was measured 24 h after infection. As shown in
Fig. 2C, MVA infection induced the accumulation of high levels of
PGE2 in C3HA cell culture supernatants.
These results show that MVA can induce the production of
PGE2 in vitro by cells of both human and murine origin, which
may have important implications for the immune response
generated by MVA-based vaccines.Viral gene expression is required for MVA-induced PGE2 production
To establish the kinetics of MVA-induced PGE2 production in
C3HA cells, the accumulation of PGE2 in culture supernatants
was measured by ELISA at various times post infection. As shown
in Fig. 3A, PGE2 production was minimal until approximately
12 h post infection. Whereafter, between 12 h and 24 h post
infection there was a dramatic increase in PGE2 production. The
long delay between MVA infection and the onset of PGE2
accumulation was in marked contrast to the response seen in
control cells treated with PGE2-inducing ligands, such as PMA, or
lipopolysaccharide (LPS) (Fig. 3A, and data not shown). This
delayed response suggested that production of PGE2 in response
to poxvirus infection might not be mediated through interaction
of the virus particles with a cellular receptor but instead might
require entry of the virus into the cell and expression of viral
gene products. To address this question, inoculations were
performed with inactivated virus preparations. Mild heat treat-
ment (55 1C, 1 h) of poxvirus particles renders them unable to
initiate viral protein synthesis after entry into cells, but does not
disrupt their structure (Harper et al., 1978). Infection of C3HA
cells with heat-inactivated MVA resulted in levels of PGE2
accumulation that were not signiﬁcantly different from those
of mock-infected control cells (Fig. 3B), which indicates that viral
gene expression is required for the production of PGE2 in
response to infection by MVA. In contrast, C3HA cells infected
with MVADudg mutants that are defective in late gene expres-
sion (Garber et al., 2009) produced high levels of PGE2 (data not
shown). Taken together, these results suggest that expression of
one or more viral early gene products is sufﬁcient to induce PGE2
production in MVA-infected cells.
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Fig. 3. Viral gene expression is required for MVA-induced PGE2 production. (A) C3HA
cells were mock-infected, treated with PMA (10 ng/ml), or infected with MVA at
5 PFU/cell. Culture supernatants were collected 2, 6, 12, or 24 h after infection and
concentrations of PGE2 were measured by ELISA. Representative data from three
independent experiments are shown. (B) Cells were mock-infected, or infected with
MVA or heat-inactivated (HI) MVA preparations, each at 5 PFU/cell. Culture super-
natants were collected 24 h after infection and concentrations of PGE2 were
determined by ELISA. Data are means and SEM from two independent experiments.
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Fig. 4. MVA infection stimulates delayed AA release frommurine ﬁbroblasts. (A) C3HA
cells were radiolabeled with [3H]AA overnight and then mock-infected, treated with
PMA (10 ng/ml), or infected withMVA or heat-inactivated (HI) MVA preparations, each
at 5 PFU/cell. Culture supernatants were collected 0, 2, 6, 12, and 24 h after infection
and 200 ml aliquots were subjected to liquid scintillation counting to determine the
release of [3H]AA (CPM). Data plotted are means and SEM from six independent
experiments for mock-infected and virus-infected cultures, and from two independent
experiments for HI virus cultures. (B) C3HA cells were radiolabeled with [3H]AA
overnight and treated with cPLA2 inhibitor (2.5 mM), or solvent control (DMSO). Cells
were stimulated with PMA (10 ng/ml) either 15 min or 22 h after the addition of cPLA2
inhibitor. Culture supernatants were collected 2 and 24 h after addition of the cPLA2
inhibitor and 200 ml aliquots were subjected to liquid scintillation counting to
determine the release of [3H]AA (CPM). Data plotted are expressed as mean percent
inhibition by cPLA2 inhibitor treatment compared to solvent control, calculated from
the three independent experiments. (C) C3HA cells were radiolabeled with [3H]AA and
mock infected, or infected with MVA in the presence of cPLA2 inhibitor (2.5 mM), or
solvent control (DMSO). Infected cells were incubated for 24 h in medium supple-
mented with cPLA2 inhibitor, or DMSO, and 200 ml aliquots were subjected to liquid
scintillation counting to determine the release of [3H]AA (CPM). Data are means and
SEM from two independent experiments.
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those of PGE2 production and also requires viral gene expression
Relatively few studies have explored the liberation of AA in
response to virus infection. As shown in Fig. 4A, the release of AA
from MVA-infected C3HA cells was markedly delayed relative to
the onset of infection, with the preponderance occurring between
12 h and 24 h post infection. The kinetics of AA release in
response to MVA infection closely paralleled those of PGE2
accumulation. Experiments conducted with heat-inactivated
virus preparations showed that, as for the production of PGE2,
the release of AA from MVA-infected cells was almost entirely
dependent on viral gene expression (Fig. 4A). The dependence of
the initiation of AA release on viral gene expression likely
contributes to the relatively slow response to poxvirus infection
when compared to the responses induced by treatment of C3HA
cells with proinﬂammatory ligands, such as PMA or LPS (Fig. 4A,
and data not shown). These ligands (Barbour et al., 1998; Gijon
et al., 2000), as well as the few viruses that have been investigated
(Culver and Laster, 2007; Liu et al., 2005), cause AA release via
activation of cPLA2. This prompted us to evaluate the role of cPLA2
in MVA-induced AA release.
Because of the relatively long time-course required to study
AA release from MVA-infected cells, we ﬁrst conducted control
experiments to determine whether a cell-permeable, cPLA2-speciﬁc
inhibitor (Seno et al., 2000) would remain effective throughout a
24 h incubation. Identical cultures of C3HA cells were labeled with[3H]–AA and then treated with either the cPLA2 inhibitor (2.5 mM) or
the solvent control (DMSO) and incubated at 37 1C. The relative
effectiveness of the cPLA2 inhibitor between 0–2 h and 22–24 h of
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Fig. 5. MVA-induced COX-2 is required for PGE2 production by infected murine
ﬁbroblasts. (A) C3HA cells were mock-infected, treated with PMA (10 ng/ml), or
infected with MVA at 5 PFU/cell in the presence of solvent control (DMSO), or the
COX-2-speciﬁc inhibitor, NS-398 (1 mM). Culture supernatants were collected 24 h
after infection and PGE2 concentrations were measured by ELISA. Data are means
and SEM from three independent experiments. (B) C3HA cells were infected with
MVA at 5 PFU/cell (5), or 0.01 PFU/cell (0.01), and 24 h after infection, cells were
ﬁxed, permeabilized, and immunostained with anti-E3L primary mAb and TRITC-
labeled secondary antibody to detect infected cells, and anti-COX-2 primary
antibody and FITC-labeled secondary antibody to measure COX-2 accumulation.
DAPI staining was used to visualize uninfected as well as infected cells. Images
were captured with constant exposure times to show intensity differences, and
representative ﬁelds are shown. (C) C3HA cells were mock-infected, or infected
with MVA at 5 PFU/cell. Cell lysates were prepared 2, 6, 12, or 24 h after infection.
Lysates (10 mg) were resolved by SDS-PAGE and immunoblotted to detect COX-2
and b-actin. The near-infrared ﬂuorescence intensity (integrated intensity) of each
COX-2-speciﬁc band was measured with the Li-Cor Odyssey system, and was
normalized to respective b-actin controls. Protein quantiﬁcation data are means
and SEM from three (2 h, 6 h, 12 h), or ﬁve (24 h), independent experiments.
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bitor-treated and control cultures during each of these time win-
dows. As shown in Fig. 4B, the cPLA2 inhibitor was able to block
PMA-stimulated AA release throughout the 24 h time-course of the
experiment. However, the cPLA2 inhibitor did not reduce the
accumulation of AA in culture supernatants of MVA-infected C3HA
cells (Fig. 4C). These data suggest that, in contrast to other viruses
that have been studied, MVA-induced AA release is primarily
dependent on a phospholipase, or phospholipases, other than cPLA2.
MVA-induced PGE2 production requires COX-2 activity and COX-2
accumulates in infected cells
Of the two predominant COX isoforms, COX-2 is most often
associated with inducible PGE2 synthesis (Smith et al., 1996). We
used a cell-permeable, COX-2-selective inhibitor, NS-398, to
evaluate the contribution of COX-2 activity to the production of
PGE2 during MVA infection. We found that NS-398 effectively
suppressed the accumulation of PGE2 in MVA-infected cell cul-
tures, as well as in PMA-stimulated control cultures (Fig. 5A).
These results show that essentially all of the PGE2 production by
MVA-infected C3HA cells is dependent on the activity of COX-2.
Next, we utilized immunoﬂuorescence microscopy to determine
if COX-2 protein accumulation was induced speciﬁcally in MVA-
infected C3HA cells. By 24 h after infection with MVA (5 PFU/cell),
C3HA cells had noticeably elevated COX-2 protein accumulation
compared to mock-infected controls (Fig. 5B). MVA infection was
conﬁrmed by immunoﬂuorescent detection of the viral E3L protein
in these cells. To determine whether COX-2 accumulation was
induced in a cell-autonomous manner by the virus infection or
whether uninfected bystander cells in the culture also accumulated
COX-2, cells were infected with MVA at 0.01 PFU/cell. COX-2
accumulated above background levels in virus-infected cells, but
not in uninfected cells in the culture (Fig. 5B). This result shows that
the accumulation of COX-2 is induced speciﬁcally during MVA
infection of C3HA cells. Further, in combination with our results
showing that COX-2 activity was required for MVA-induced PGE2
synthesis, it suggests that the PGE2 detected in culture supernatants
is produced predominantly by MVA-infected cells and not by
uninfected bystander cells within the culture system.
To evaluate the time-course of COX-2 accumulation during MVA
infection in more detail, equal amounts (10 mg) of mock-infected or
MVA-infected C3HA cell lysates, collected at various times post
infection, were subjected to quantitative immunoblot analysis for
the COX-2 protein (Fig. 5C). This analysis revealed that the level of
COX-2 protein present in mock-infected cells declined steadily
during the 24 h incubation in medium containing low serum. In
contrast, the level of COX-2 in MVA-infected cells began to rise by
6 h post infection, and by 24 h post infection it was elevated 80-
fold relative to the level in mock-infected cells. Thus, these results
conﬁrm those obtained by immunoﬂuorescence microscopy and
show that COX-2 protein levels begin to rise in MVA-infected cells
prior to the release of AA, or the accumulation of PGE2.
MVA-induced COX-2 accumulation and PGE2 biosynthesis are not
dependent on canonical NF-kB signaling via p65/RelA
Transcriptional regulation of COX-2 synthesis can involve a multi-
tude of transcription factors, which include NF-kB, AP-1, NFAT, CRE,
and others (Iniguez et al., 2000; Kang et al., 2006). The contribution of
each of these transcription factors to the regulation of COX-2 gene
expression likely varies among particular types of cells and different
stimuli. For several viruses, including encephalomyocarditis virus
(EMCV), dengue virus, hepatitis C virus, and latent Epstein-Barr virus
(EBV), the activation of NF-kB signaling has been implicated either in
COX-2 induction, or the accumulation of PGE2, in response toinfection (Liou et al., 2008; Murono et al., 2001; Steer et al., 2003;
Waris and Siddiqui, 2005). Alternatively, interference with the
activation of NF-kB has been implicated in the suppression of PGE2
production that occurs upon EBV lytic infection (Savard et al., 2000).
MVA is unique in that it activates canonical NF-kB signaling via
p65/RelA, while related orthopoxviruses, including VAC, encode
multiple factors that suppress NF-kB activation (Oie and Pickup,
2001). To test directly whether canonical NF-kB signaling via
p65/RelA was required for MVA-induced production of PGE2, we
utilized a recombinant form of MVA (MVA/K1L) that contains a
p65/RelA
E3L
DAPI p65/RelA
E3L
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MVA MVA/K1L
Fig. 6. Expression of the VAC K1L gene in MVA prevents MVA-induced NF-kBp65 nuclear translocation. C3HA cells were mock-infected, or infected with MVA or MVA/K1L
each at 5 PFU/cell. At 4 h after infection, cells were ﬁxed, permeabilized, and immunostained with anti-E3L primary mAb and TRITC-labeled secondary antibody to detect
infected cells, and anti- p65/RelA primary antibody and FITC-labeled secondary antibody to discern cellular localization of p65/RelA. DAPI staining was used to visualize
nuclear regions. Representative ﬁelds are shown.
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Fig. 7. MVA-induced PGE2 biosynthesis is not dependent on NF-kB activation.
(A) C3HA cells were mock-infected, or infected with MVA or MVA/K1L at 5 PFU/cell.
Cell lysates were prepared 2, 12, or 24 h after infection. Lysates (10 mg) were
resolved by SDS-PAGE and immunoblotted to detect COX-2 and b-actin. Immuno-
labeled protein bands were visualized using the Li-Cor Odyssey system. Three
independent experiments were conducted and a representative gel image is shown.
(B) C3HA cells were radiolabeled with [3H]AA overnight and then mock-infected, or
infected with MVA or MVA/K1L, each at 5 PFU/cell. Culture supernatants were
collected 0, 2, 6, 12, and 24 h after infection and 200 ml aliquots were subjected to
liquid scintillation counting to determine release of [3H]AA (CPM). Data plotted are
means and SEM, from four independent experiments. (C) C3HA cells were mock
infected, or infected with MVA or MVA/K1L, each at 5 PFU/cell. Culture supernatants
were collected 24 h after infection and concentrations of PGE2 were determined by
ELISA. Data are means and SEM from three independent experiments.
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place of the disrupted MVA K1L gene. We and others have demon-
strated that expression of the VAC K1L gene is sufﬁcient to suppressMVA-induced IkBa degradation and subsequent activation of NF-kB
(Lynch et al., 2009; Shisler and Jin, 2004). As described for other cell
types, the infection of C3HA cells with MVA resulted in the activation
of NF-kB signaling, which could be demonstrated by translocation of
p65/RelA to the nucleus of infected cells (Fig. 6). In marked contrast,
p65/RelA remained in the cytoplasm of cells infected with MVA/K1L
(Fig. 6), thus conﬁrming that canonical NF-kB signaling is suppressed
in C3HA cells by expression of the K1L gene.
The results described above substantiate the use of direct
comparisons between MVA and MVA/K1L to determine the con-
tribution of canonical NF-kB signaling to MVA-induced PGE2 bio-
synthesis. The analysis of cell lysates by immunoblotting revealed
that similar amounts of COX-2 protein were present in C3HA cells
infected with MVA or MVA/K1L (Fig. 7A). This indicated that, in
contrast to the ﬁndings made for some other viruses, the activation
of canonical NF-kB signaling via p65/RelA is not required for COX-2
protein accumulation during MVA infection. Additionally, there was
no difference in the kinetics of AA liberation from cells infected with
MVA or MVA/K1L (Fig. 7B), nor was there any reduction in the
accumulation of AA or PGE2 in culture supernatants of MVA/K1L-
infected cells (Fig. 7C). Thus, neither COX-2 accumulation nor PGE2
biosynthesis are dependent on the activation of canonical NF-kB
signaling in MVA-infected C3HA cells.Discussion
This study extends previous reports (Palumbo et al., 1993, 1994)
and demonstrates for the ﬁrst time that MVA infection can result in
PGE2 production in the absence of exogenous PG precursors and
A23187. Most notably, MVA infection was shown to induce PGE2
production from human macrophage-like cells and from murine
DCs. This study is also the ﬁrst to describe release of the endogenous
eicosanoid precursor, AA, from cellular membranes in response to
poxvirus infection. We showed that COX-2 accumulation is induced
during MVA infection and that COX-2 is required for PGE2 produc-
tion by MVA-infected cells. Finally, we found that the ability of MVA
to activate canonical NF-kB signaling via p65/RelA did not con-
tribute to MVA-induced COX-2 accumulation or PGE2 production.
The ability of poxvirus-infected cells to metabolize AA has been
demonstrated in previous studies conducted with BS-C-1 cells
(Palumbo et al., 1993, 1994). Our results extend this observation,
and demonstrate that MVA infection of human THP-1 cells, murine
DCs, or murine C3HA ﬁbroblasts, results in the release of AA from cell
membranes, metabolism of AA, and accumulation of PGE2. However,
MVA infection alone was unable to stimulate either the release of AA
from BS-C-1 cell membranes, or the accumulation of PGE2 in culture
supernatants of BS-C-1 cells. We therefore speculate that, in
the absence of exogenously added precursor molecules, a lack of
available substrate (AA) accounts for the failure of poxvirus-infected
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PGE2 production in THP-1 cells, murine DCs and C3HA cells, and the
lack of PGE2 production in MVA-infected BS-C-1 cells, implicates the
contribution of cell-speciﬁc factors in inﬂuencing the poxvirus-
induced PG response. The underlying causes of such cell type
speciﬁcity are likely to be multifactorial. For example, AA release
and induction of COX-2 expression may be activated via distinct
signal transduction pathways in response to MVA infection. As a
result, a cell type-speciﬁc failure to activate either one of these signal
transduction pathways could prevent MVA-induced PGE2 production.
The infection of human THP-1 macrophage-like cells or murine
DCs with MVA caused high levels of PGE2 to accumulate in culture
supernatants compared to mock-infected controls, and these results
were recapitulated in the C3HA mouse ﬁbroblast cell line. Accord-
ingly, C3HA cells were used as a model system to gain insight into
the molecular factors involved in MVA-induced PGE2 biosynthesis.
We found that the kinetics of MVA-stimulated AA release closely
paralleled those of PGE2 accumulation, which is consistent with the
possibility that the availability of AA, the initial substrate for the
pathway, is rate-limiting for PGE2 biosynthesis. Additionally, we
found that COX-2 speciﬁcally accumulated in MVA-infected cells,
and COX-2 enzyme activity was required for MVA-induced PGE2
production. These results are all consistent with established models
of inducible PGE2 production (Smith, 1989; Smith et al., 1996).
One of the more striking ﬁndings of this study was that in
MVA-infected cells, AA release and PGE2 accumulation were delayed
by approximately 12 h relative to the onset of infection. And, even
more remarkably, AA release was found to be independent of cPLA2
enzyme activity. The delayed release of AA observed upon MVA
infection contrasts with the more rapid, cPLA2-dependent, release
described following infection of C3HA cells with adenovirus (Culver
and Laster, 2007) or by stimulation of these cells with PMA, or LPS.
Experiments with heat-inactivated MVA preparations andMVADudg
mutants demonstrated that the delayed response may, at least in
part, be due to the requirement for viral early gene expression for
the activation of AA release and subsequent PGE2 synthesis. Con-
ceivably, it might take up to 12 h for one or more viral proteins to
accumulate to a critical threshold level that can directly activate the
signal transduction leading to AA release and PGE2 production.
Equally, though, AA release may be delayed simply because it is an
indirect effect of viral infection. A third possibility, which is not
mutually exclusive with the others, is that the utilization of non-
cPLA2-dependent mechanisms for AA release may contribute to the
atypical kinetics that we observed for MVA-infected cells. It remains
to be determined whether AA release from MVA-infected cells relies
on known cellular or viral phospholipases (Baek et al., 1997), or
whether yet-uncharacterized enzymes may be implicated. The
results of this study raise the interesting possibility that such non-
canonical mechanisms for AA release may contribute to eicosanoid
production during viral infections more generally.
Amongst orthopoxviruses, the uncommon ability of MVA to
activate canonical NF-kB signaling via p65/RelA is presumed to be
a signiﬁcant contributing factor in determining the immune response
to infection. Evidence for the involvement of NF-kB in the induction
of COX-2 expression and the subsequent production of PGE2 has
been described in several systems (Steer et al., 2003; Yamamoto
et al., 1995). However, our experiments in whichMVAwas compared
to MVA/K1L, a recombinant virus which does not induce IkBa
degradation or nuclear translocation of p65/RelA in infected cells,
revealed that canonical NF-kB signaling via p65/RelA is not required
for the liberation of AA, the accumulation of COX-2, or PGE2
production by MVA-infected C3HA cells. Although the ability to
activate canonical NF-kB signaling may be a crucial determinant of
many biological responses to MVA infection, it appears not to be
important for the PG response. In addition, it has recently been
shown that MVA infection activates double-stranded RNA-activatedprotein kinase (PKR), and that PKR activation is inhibited by expres-
sion of K1L (Lynch et al., 2009; Willis et al., 2009). Therefore, our
results for MVA/K1L also suggest that MVA-induced production of
PGE2 is not mediated by the activation of PKR. A similar lack of
dependence on PKR has been described previously for PGE2 produc-
tion by EMCV-infected macrophages (Steer et al., 2003).
The robust production of PGE2 in response to MVA infection is
particularly interesting because of the potential for widespread use of
MVA as a vaccine and vaccine vector. Vaccine-induced production of
PGE2 is expected to have roles in inﬂuencing the overall immune
response that is generated. In particular, PGE2 signaling may con-
tribute to the Th2 response initiated by MVA-based vaccines.
Although MVA is highly regarded for its ability to induce cell-
mediated immune responses, a Th2 component that drives the
production of neutralizing antibodies is also generated (Earl et al.,
2004; Wyatt et al., 2004). The humoral component of MVA-induced
immune responses is also evident in cytokine proﬁles measured in
mouse spleen homogenates one and two days after inoculation with
MVA, which indicated elevated levels of IL-6, but not IL-12 or IFN-g
(Ramirez et al., 2000). Additionally, at high inoculum doses, MVA
preferentially induced the production of IgG1, a Th2 antibody isotype,
over IgG2a (Ramirez et al., 2000). These Th2-biased responses
correlate with known effects of PGE2 signaling (Harris et al., 2002;
Hinson et al., 1996) and suggest that manipulation of MVA-induced
PGE2 productionmight allow customization of the immune responses
generated by MVA-based vaccines. In particular, enhanced Th1
responses might be generated by an MVA-based vaccine vector that
is rendered incapable of inducing PGE2 production.
Recent studies have shown that PGs can mediate various effects
on vaccine-induced immune responses. In several reports, the
inhibition of COX-2 in combination with various anti-cancer vac-
cines has been shown to signiﬁcantly augment vaccine efﬁcacy
(Basu et al., 2006; Haas et al., 2006; Mukherjee et al., 2009; Zeytin
et al., 2004). It is thought that COX-2 inhibition, via the concomitant
decrease in PGE2 production, leads to reduced activation of indo-
leamine 2,3-dioxygenase and increased Th1 cytokine production,
which facilitates a more effective CTL response. In contrast, follow-
ing vaccination with human papillomavirus type 16 virus-like
particles, COX-2 activity was shown to be essential for the genera-
tion of an optimal neutralizing antibody response and for memory
B-cell expansion (Ryan et al., 2006). Likewise, COX-2 activity has
recently been shown to be required for an optimal antibody
response to infection with VAC (Bernard et al., 2010). Based on
these results, and those of the current study, it may be hypothesized
that MVA-induced PGE2 signaling contributes generally to the ability
of MVA-based vaccines to generate antibody responses.Materials and methods
Reagents and antibodies
All of the fetal bovine serum (FBS), cell culture media, and cell
culture reagents were purchased from Gibco unless otherwise
stated. The recombinant GM-CSF and IL-4 were purchased from
R&D Systems. The COX-2-speciﬁc inhibitor NS-398 was purchased
from Cayman Chemical Company. The speciﬁc cPLA2 inhibitor (N-
{(2S,4R)-4-(Biphenyl-2-ylmethyl-isobutyl-amino)-1-[2-(2,4-diﬂuoro-
benzoyl)-benzoyl]-pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-
5-ylidenemethyl)-phenyl]acrylamide, HCl) was purchased from
Calbiochem. 4-bromo A-23187 (A23187) was purchased from
Invitrogen. Phorbol 12-myristate 13-acetate (PMA) was pur-
chased from Biomol International. The radiolabeled [5,6,8,9,11,
12,14,15-3H(N)]-arachidonic acid ([3H]AA) was purchased from
Perkin Elmer. The COX-2-speciﬁc rabbit polyclonal antibody was
purchased from Cayman Chemical. The monoclonal antibody
J.J. Pollara et al. / Virology 428 (2012) 146–155 153(mAb) speciﬁc to p65/RelA (C-20) was purchased from Santa Cruz
Biotechnology. Inc. The murine mAb speciﬁc to b-actin was
purchased from Sigma-Aldrich. Ascites ﬂuid containing murine
mAb (TW2.3) speciﬁc to the VAC early gene product E3L (Yuwen
et al., 1993) was a generous gift from Dr. Jack Bennink (National
Institutes of Health). The tetramethylrhodamine isothiocyanate
(TRITC)-conjugated goat anti-mouse, and FITC-conjugated goat
anti-rabbit antibodies were obtained from Sigma-Aldrich. The
secondary antibodies used with the Odyssey Infrared Imaging
System, goat anti-mouse IRDye 680 and goat anti-rabbit IRDye
800CW, were purchased from Li-Cor Biosciences.
Cell culture and generation of murine bone marrow derived DCs
C3HA murine ﬁbroblasts (Gooding, 1979) were cultured in
DMEM supplemented with 1 mM sodium pyruvate and 5% FBS.
BS-C-1 cells were from the American Type Culture Collection
(ATCC, CCL-26) and were cultured in DMEM supplemented with
10% FBS. THP-1 human monocytes (ATCC, TIB-202) were cultured
in RPMI 1640 supplemented with 0.05 mM 2-mercaptoethanol,
100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM L-gluta-
mine, and 10% FBS. Cell lines were maintained at 37 1C in a 5% CO2
atmosphere. Bone marrow cells were harvested from 12 to 24
week-old female C57BL/6 mice (Charles Rivers Labs). Procedures
for the use and care of mice were conducted in accordance
with the National Institutes of Health guidelines, and protocols
approved by Duke University’s Institutional Animal Care and
Use Committee. Bone marrow cells were cultured to generate
DCs, as described by Lee et al. (2005). Brieﬂy, bone marrow
progenitor cells were cultured in DC medium (RPMI 1640 supple-
mented with 5% heat-inactivated FBS, 100 units/ml penicillin,
100 mg/ml streptomycin, 1 mM sodium pyruvate, 1 MEM non-
essential amino acids, 0.5 MEM essential amino acids, 10 mM
HEPES, 2 mM L-glutamine, 55 mM b-mercaptoethanol, and 10 ng/ml
each of recombinant mouse GM-CSF and IL-4). After three days, the
adherent cells were washed and replenished with fresh DC medium
and cultured for three additional days. Non-adherent, immature DCs,
were harvested at day six and cultured in DC medium without
cytokines for all experiments.
Viruses and infections
The viruses employed in this study were MVA (ATCC VR-1566),
VAC strain Western Reserve (ATCC VR-1354), and MVA/K1L, a
recombinant MVA virus which contains the K1L gene from VAC
strain Western Reserve in place of the disrupted K1L gene of MVA
(Lynch et al., 2009). The replication-defective MVADudg mutants,
vDG014 and vDG027, which were propagated on their helper cell
line, CAN20 (Garber et al., 2009) were also used. The MVADudg
mutants and helper cell line were kindly provided by Dr. David
Garber (Emory University). Unless otherwise indicated, all virus
infections were conducted at 5 PFU/cell for 1 h at 37 1C in medium
containing 2.5% FBS. Where indicated, virus preparations were heat-
inactivated by incubation for 1 h at 55 1C.
Quantitative PGE2 ELISA
The accumulation of PGE2 in cell culture supernatants was
measured using speciﬁc immunoassays (Assay Designs). Brieﬂy
2.5104 C3HA cells were plated into 24-well ﬂat bottom tissue
culture plates (Corning Incorporated) and incubated overnight at
37 1C to allow the cells to adhere. For THP-1 human monocytes,
the cells were plated at 5105 cells per well and cultured at 37 1C
for 48 h in media containing 10 nM PMA to allow differentiation
into adherent macrophage-like cells. When DCs were used, 5105
cells per well were plated, followed by incubation for 1 h at 37 1Cto allow the cells to adhere. The virus infections and experimental
treatments were conducted as indicated, and cell supernatants
were collected at various times after infection or treatment. The
supernatants were brieﬂy centrifuged to remove large debris, and
the immunoassays were performed according to the manufac-
turer’s instructions. The absorbance was measured with a Polar-
Star microplate reader (BMG Labtechnologies) and the
concentration of PGE2 was determined by comparison to a
standard curve. In experiments conducted using the COX-2 spe-
ciﬁc inhibitor, NS-398, the cells were plated, infected, and incu-
bated in media that were supplemented with the drug (1 mM), or
the solvent control (DMSO).
Immunoﬂuorescence microscopy
8-well glass chamber slides (Nalge Nunc International) were
seeded with 2104 C3HA cells in 2.5% FBS DMEM and incubated
at 37 1C overnight. The cells were then mock-infected or infected
with MVA or MVA/K1L and incubated at 37 1C for the times
indicated. The cells were ﬁxed in PBS containing 4% formaldehyde
for 20 min at room temperature and then washed twice in PBS
containing 3% BSA. The cells were then permeabilized with PBS
containing 0.1% Triton X-100 for 5 min, washed twice in PBS
containing 3% BSA, and incubated with the primary antibodies in
0.3% BSA for 1 h. The cells were then again washed twice in PBS
containing 3% BSA and incubated with the secondary antibodies
in PBS containing 0.3% BSA for 30 min. Subsequently, the cells
were washed twice in PBS containing 3% BSA and mounted in an
anti-fade slide mount containing 40,6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories, Inc.). Microscopy was conducted on a
Zeiss Axioskop 2 Plus and the images were captured using Spot
Advanced software (Diagnostic Instruments, Inc.).
[3H]AA release assays
For each experimental condition, a total of 5105 C3HA cells
were seeded into T25 tissue culture ﬂasks (Becton Dickinson) and
incubated at 37 1C overnight in medium containing 0.1 mCi/ml
[3H]AA. After labeling, the cells were washed two times with
HBSS. Fresh medium supplemented with 2.5% FBS was added to
the ﬂasks and the cells were incubated at 37 1C for 2 h to allow for
the spontaneous release of the radiolabel. The cells were then
washed again with HBSS and infected as indicated for 1 h at 37 1C.
Following infection, 2.5% FBS DMEM was added to each ﬂask to a
ﬁnal volume of 5.5 ml and the cultures were incubated at 37 1C.
At the indicated times after infection, 250 ml of the supernatant
were collected from each ﬂask and brieﬂy centrifuged to remove
debris. Liquid scintillation counting was performed on 200 ml
samples of this supernatant using a Beckman Coulter model LS 5801.
Immunoblotting and quantitative immunoblotting
Monolayers of mock-infected or virus-infected C3HA cells
were solubilized in lysis buffer (50 mM HEPES (pH 7.4), 1 mM
EGTA, 1 mM EDTA, 0.2 mM sodium orthovanadate, 2 mM PMSF,
and 0.5% SDS) and collected by scraping. The total protein
concentration of the samples was determined using the Bio-Rad
DC protein assay (Bio-Rad Laboratories, Inc). Equal amounts of
total protein (10 mg) were loaded onto 12% or 16% polyacrylamide
Tris-glycine gels and separated by electrophoresis on a Novex
MiniCell System (Invitrogen Life Technologies). The proteins were
transferred to Immobilon-FL PVDF membranes (Millipore) and
blocked for 1 h in Odyssey Blocking Buffer (Li-Cor Biosciences).
The primary antibodies were diluted in 0.1% Tween-20 Odyssey
Blocking Buffer and incubated with the membrane overnight
at 4 1C (COX-2 and mPGES-1) or for 1 h at room temperature
J.J. Pollara et al. / Virology 428 (2012) 146–155154(b-actin). The membranes were washed extensively in PBS con-
taining 0.1% Tween-20. Secondary antibodies speciﬁcally
designed for use with the Li-Cor Odyssey system were diluted
in 0.1% Tween-20 Odyssey Blocking buffer and incubated for
45 min at room temperature, followed by extensive washing with
PBS containing 0.1% Tween-20. The band visualization and quan-
tiﬁcation was completed on a Li-Cor Odyssey scanning system
running Odyssey 2.1 software (Li-Cor Biosciences). The integrated
intensity of each speciﬁc band of interest was measured and
normalized to the respective b-actin control band to account for
any minor variations in total protein loads.Acknowledgments
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